(Q36223165)

12 August 2017

1 reference

title

Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? (English)

1 reference

12 August 2017

John L Reid

1

1 reference

12 August 2017

publication date

1 March 2005

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

15-24

1 reference

AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Losartan prevents thromboxane A2/prostanoid (TP) receptor mediated increase in microvascular permeability in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Functional interaction between losartan and central tachykinin NK3 receptors in the conscious rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Interactions of nonpeptide angiotensin II receptor antagonists at imidazoline/guanidinium receptor sites in rat forebrain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

What can knockout mice contribute to an understanding of hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Hypertension and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Sympathetic deactivation as a goal of nonpharmacologic and pharmacologic antihypertensive treatment: rationale and options

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Beta-blockers for congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

The alpha2 -adrenergic receptors in hypertension and heart failure: experimental and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Roles of PPARs in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

The PPARs: from orphan receptors to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

PPAR(gamma) and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Thiazolidinedione-associated congestive heart failure and pulmonary edema

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Role of platelets in the pathophysiology of acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

The endothelium and platelets in cardiovascular disease: potential targets for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Part 1. Uric acid and losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Uric acid and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Serum uric acid as a cardiovascular risk factor for heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Neutral effect of valsartan on serum uric acid and renal function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Renal effects of angiotensin II receptor blockade in normotensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Uricosuric effect of losartan in patients with renal transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2005.002

21 January 2018

Identifiers

DOI

10.3317/JRAAS.2005.002

1 reference

12 August 2017

1 reference